Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alprazolam

FDA-approved product (tablet, oral), marketed as Alprazolam, Niravam, Xanax and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Alprazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Generalized anxiety disorder
  • Panic disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alprazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alprazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

    NCT00647634 · start 2004-08

    Registered record
    Registry ID
    NCT00647634
    Conditions
    Healthy
    Interventions
    Alprazolam Extended-Release Tablets 3 mg; Xanax XR® Tablets (3 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08
    Completion
    2004-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam Extended-Release Tablets 3 mg; Xanax XR® Tablets (3 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

    NCT00634790 · start 2004-05

    Registered record
    Registry ID
    NCT00634790
    Conditions
    Panic Disorder
    Interventions
    alprazolam XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-05
    Completion
    2004-10
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    Interventionalprazolam XR
    PhasePhase 4
    Registry statusTerminated

  • A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

    NCT00635531 · start 2004-04

    Registered record
    Registry ID
    NCT00635531
    Conditions
    Panic Disorder
    Interventions
    placebo; alprazolam XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-04
    Completion
    2004-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    Interventionplacebo; alprazolam XR
    PhasePhase 4
    Registry statusTerminated

  • Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety

    NCT00004373 · start 1997-03

    Registered record
    Registry ID
    NCT00004373
    Conditions
    Anxiety Disorder; Panic Disorder
    Interventions
    alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-03
    Completion
    2001-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorder; Panic Disorder
    Interventionalprazolam
    PhasePhase 2
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

    NCT00912145 · start 1996-02

    Registered record
    Registry ID
    NCT00912145
    Conditions
    Anxiety
    Interventions
    Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-02
    Completion
    1996-02
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety
    InterventionAlprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
    PhasePhase 1
    Registry statusCompleted